Nuvalent Extended Access Program Now Available in Canada

Montreal, Feb. 27, 2025 — ALK Positive Canada is pleased to announce that the Nuvalent Extended Access Program is now available in Canada, offering eligible patients access to Neladalkib, Nuvalent’s targeted therapy for ALK-positive lung cancer.

Who Is Eligible?

Patients may qualify for the program if they:

• Have previously been treated with both Lorlatinib and chemotherapy and have exhausted standard treatment options, or
• Have a medical reason preventing them from receiving Lorlatinib or chemotherapy (must be documented by their oncologist)

How to Apply

• Patients must work with their oncologist to submit an application to Nuvalent.
• Dr. Geoffrey Liu is available to assist both patients and oncologists in preparing applications. He can be reached at geoffrey.liu@uhn.ca.

ALK Positive Canada remains committed to supporting patients in accessing innovative treatments. For more information, please reach out to your healthcare provider or contact our team.

In support,

ALK Positive Canada Team